TECX TECTONIC THERAPEUTIC INC.

Tectonic Therapeutic to Participate in March Investor Conferences

Tectonic Therapeutic to Participate in March Investor Conferences

WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2025.

TD Cowen 45th Annual Health Care Conference 
Date:March 5, 2025
Time:9:50 AM EST
Location:Boston, MA
Format:Corporate Presentation
Presenter:Alise Reicin, MD, President and Chief Executive Officer
Webcast: 



Leerink Partners Global Healthcare Conference
Date: March 11, 2025
Time:11:20 AM EDT
Location:Miami, FL
Format:Fireside Chat
Presenters:Daniel Lochner, Chief Financial Officer, and Marc Schwabish, PhD, Chief Business Officer
Webcast: 
  

Both live webcasts can also be accessed under “” on the Investors section of the Tectonic website at . Once these conferences have concluded, a replay of the two webcasts will be available on the Company’s website for approximately 90 days.

The Tectonic management team will host one-on-one meetings during both conferences. Interested investors should contact their TD Cowen and/or Leerink representative to schedule meetings.

About Tectonic

 is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”). Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit and follow on .



Contacts:

Investors:
Dan Ferry
LifeSci Advisors
(617) 430-7576
 

Media:
Kathryn Morris
The Yates Network
(914) 204-6412
 
EN
20/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TECTONIC THERAPEUTIC INC.

 PRESS RELEASE

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Indep...

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) --  (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more ...

 PRESS RELEASE

Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX210...

Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026 WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- . (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), announced that it will host a virtual key opinion leader (KOL) event and TX2100 discussion on Tuesday, February 24, 2026 from 11:00 a.m. to 12:30 p.m. ET. ...

 PRESS RELEASE

Tectonic Therapeutic to Participate in December Investor Conferences

Tectonic Therapeutic to Participate in December Investor Conferences WATERTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in December 2025. Piper Sandler 37th Annual Healthcare Conference Date:Time:Location:Format:Presenters:Webcast:December 2, 20253:30 PM ESTNew Yo...

 PRESS RELEASE

Tectonic Therapeutic Announces Third Quarter 2025 Financial Results an...

Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights Positive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”)Expect to initiate TX2100 Phase 1 clinical trial in healthy volunteers in Q1’2026 as a potential treatment for Hereditary Hemorrhagic Telangiectasia (“HHT”)TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety ...

 PRESS RELEASE

Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Par...

Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH‑HFrEF”)TX45 was well tolerated in patients with PH‑HFrEF with no serious or severe adverse events, no clinically significant changes in blood pressure and no immune related reactionsResults support potential expansion of TX45’s addressable Group 2 PH patient population to PH...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch